Giuseppe Mele
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giuseppe Mele has a total of 429 co-authors. Here are the top co-authors by number of shared publications:
- Massimo Gentile
Azienda Ospedaliera Annunziata, Cosenza, Italy
10 shared publications Pellegrino Musto
Unit of Hematology and Stem Cell Transplantation AOUC Policlinico Bari Italy
9 shared publicationsNicola Di Renzo
Department of Hematology Hospital Vito Fazzi Lecce Italy
8 shared publicationsAngela Melpignano
Haematology and BMT Unit-"Antonio Perrino" Hospital, 72100 Brindisi, Italy
7 shared publicationsDaniele Derudas
SC di Ematologia e CTMO - Ospedale Oncologico di Riferimento Regionale “A. Businco” - ARNAS “G. Brotzu” – Cagliari - Italy
7 shared publicationsDomenico Pastore
Haematology and Stem Cell Transplant Unit, Presidio Ospedaliero A. Perrino
7 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1704-1714
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network ( EMN ) Italy
Summary: The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT) remains unclear. The aim of this real‐life study is to evaluate the effectiveness of the regimens licensed in Italy and used in a cohort of patients who relapsed during Len maintenance after AHSCT. We collected 306 patients with these features. Considering the different regimens used, most patients received isatuximab–carfilzomib–dexamethasone (Isa‐KD) (45.4%) followed by daratumumab–pomalidomide–dexamethasone (D‐PD) (19.3%) and daratumumab–bortezomib–dexamethasone (D‐VD) (12.4%). Overall, a reduced progression‐free survival (PFS) and overall survival (OS) were observed in patients with high‐risk disease features at relapse, including high lactate dehydrogenase (LDH) ( p = 0.0003 and p < 0.0001), International Staging System (ISS) ≥2 ( p < 0.0001 and p < 0.0001) and early relapse (p = 0.0017 and p = 0.0009). Considering the type of treatment, anti‐cluster of differentiation 38 (CD38) monoclonal antibodies (anti‐CD38 MoAb)‐based regimen displayed improved survival compared to the other treatment, with Isa‐KD reporting the longest PFS (22.8 months). Our data in a homogenous cohort of Len‐R patients treated at first relapse demonstrated that the anti‐CD38 MoAb‐based combinations, particularly Isa‐KD, represented the standard of care before the approval of anti‐B cell maturation antigen (BCMA) immunotherapy.
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1704-1714
Open AccessSalvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network ( EMN ) Italy
Summary: The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT) remains unclear. The aim of this real‐life study is to evaluate the effectiveness of the regimens licensed in Italy and used in a cohort of patients who relapsed during Len maintenance after AHSCT. We collected 306 patients with these features. Considering the different regimens used, most patients received isatuximab–carfilzomib–dexamethasone (Isa‐KD) (45.4%) followed by daratumumab–pomalidomide–dexamethasone (D‐PD) (19.3%) and daratumumab–bortezomib–dexamethasone (D‐VD) (12.4%). Overall, a reduced progression‐free survival (PFS) and overall survival (OS) were observed in patients with high‐risk disease features at relapse, including high lactate dehydrogenase (LDH) ( p = 0.0003 and p < 0.0001), International Staging System (ISS) ≥2 ( p < 0.0001 and p < 0.0001) and early relapse (p = 0.0017 and p = 0.0009). Considering the type of treatment, anti‐cluster of differentiation 38 (CD38) monoclonal antibodies (anti‐CD38 MoAb)‐based regimen displayed improved survival compared to the other treatment, with Isa‐KD reporting the longest PFS (22.8 months). Our data in a homogenous cohort of Len‐R patients treated at first relapse demonstrated that the anti‐CD38 MoAb‐based combinations, particularly Isa‐KD, represented the standard of care before the approval of anti‐B cell maturation antigen (BCMA) immunotherapy.
- Open Access
- 15 January 2026
- Published by Aboutscience Srl in AboutOpen
- Vol. 13 (1) , 31-41
SyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care
The management of transplant-eligible, newly diagnosed multiple myeloma is evolving with the adoption of antiCD38-based quadruplet regimens and the potential earlier use of anti-BCMA CAR T-cell therapy in lenalidomiderefractory disease. In this context, the national macroregional syMMphony project (covering Northern, Central, and Southern Italy) was developed to coordinate clinical and organizational pathways across the continuum of care, from initial autologous stem cell transplantation (ASCT) to referral for CAR T-cell therapy. The project involved structured multidisciplinary discussions within three Italian macroareas focused on four key areas: the impact of anti-CD38 quadruplets, criteria for ASCT eligibility, early identification of patients who may qualify for CAR T-cell therapy based on CARTITUDE-4, and organizational requirements for equitable access to advanced treatments. Each macroarea produced written agreements, which were then compared and harmonized during a national plenary meeting to create a final cross-regional consensus. Across all macroareas, ASCT remained central, with eligibility based mainly on overall fitness rather than age alone, and tandem transplantation reserved for select high-risk cases. Daratumumab combined with lenalidomide maintenance was recognized as an emerging post-transplant strategy, while MRD-guided modulation appeared promising but required methodological standardization and the establishment of dedicated laboratory networks. Early referral pathways for CAR T-cell therapy were increasingly seen as relevant for certain patients with lenalidomide-refractory relapse, highlighting the importance of hub-and-spoke models, resource planning, sustainable funding, and systematic collection of real-world data. Overall, the syMMphony project produced a macroregional agreement aimed at supporting more consistent and timely care pathways, aligned with evolving evidence and regulatory frameworks.
- 15 January 2026
- Published by Aboutscience Srl in AboutOpen
- Vol. 13 (1) , 31-41
Open AccessSyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care
The management of transplant-eligible, newly diagnosed multiple myeloma is evolving with the adoption of antiCD38-based quadruplet regimens and the potential earlier use of anti-BCMA CAR T-cell therapy in lenalidomiderefractory disease. In this context, the national macroregional syMMphony project (covering Northern, Central, and Southern Italy) was developed to coordinate clinical and organizational pathways across the continuum of care, from initial autologous stem cell transplantation (ASCT) to referral for CAR T-cell therapy. The project involved structured multidisciplinary discussions within three Italian macroareas focused on four key areas: the impact of anti-CD38 quadruplets, criteria for ASCT eligibility, early identification of patients who may qualify for CAR T-cell therapy based on CARTITUDE-4, and organizational requirements for equitable access to advanced treatments. Each macroarea produced written agreements, which were then compared and harmonized during a national plenary meeting to create a final cross-regional consensus. Across all macroareas, ASCT remained central, with eligibility based mainly on overall fitness rather than age alone, and tandem transplantation reserved for select high-risk cases. Daratumumab combined with lenalidomide maintenance was recognized as an emerging post-transplant strategy, while MRD-guided modulation appeared promising but required methodological standardization and the establishment of dedicated laboratory networks. Early referral pathways for CAR T-cell therapy were increasingly seen as relevant for certain patients with lenalidomide-refractory relapse, highlighting the importance of hub-and-spoke models, resource planning, sustainable funding, and systematic collection of real-world data. Overall, the syMMphony project produced a macroregional agreement aimed at supporting more consistent and timely care pathways, aligned with evolving evidence and regulatory frameworks.
- Open Access
- 9 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 858
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595
- 9 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 858
Open AccessCorrection: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595
- Open Access
- 19 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 595
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study
Background: In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma after 1–3 prior treatments. Methods: Our real-world, AENEID study aimed to evaluate the efficacy and safety of IsaKd in patients who relapsed after frontline lenalidomide treatment, poorly represented in the IKEMA trial. Specifically, in the present multicenter analysis, we enrolled eighty-two patients who received, between April 2022 and September 2024 and outside of clinical trials, at least one cycle of IsaKd as a second-line treatment at the first relapse after induction therapy, autologous stem cell transplantation (ASCT), and lenalidomide maintenance. Results: After a median follow-up time of 12.9 months (range, 1–77), the overall response rate, at least a very good partial response rate, and median progression-free survival time were 79.3%, 56.1%, and 24.4 months, respectively. This slightly lower performance compared to that in the IKEMA study may be attributed to the well-known poor prognostic impact of lenalidomide refractoriness (len-R), developed by all our patients during maintenance therapy, and to a higher proportion of patients with extramedullary disease present in our series, which was identified as the only factor significantly affecting the PFS in multivariable analysis. The median overall survival was not reached, as in the pivotal trial, while the 1-year survival probability was 85.1%. Regarding the safety profile, our findings were consistent with those of the IKEMA trial, with no new safety signals reported. Conclusions: These real-world data support the use of IsaKd as a valuable option for len-R MM patients relapsing after the first-line therapy, including ASCT and lenalidomide maintenance.
- 19 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 595
Open AccessEfficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study
Background: In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma after 1–3 prior treatments. Methods: Our real-world, AENEID study aimed to evaluate the efficacy and safety of IsaKd in patients who relapsed after frontline lenalidomide treatment, poorly represented in the IKEMA trial. Specifically, in the present multicenter analysis, we enrolled eighty-two patients who received, between April 2022 and September 2024 and outside of clinical trials, at least one cycle of IsaKd as a second-line treatment at the first relapse after induction therapy, autologous stem cell transplantation (ASCT), and lenalidomide maintenance. Results: After a median follow-up time of 12.9 months (range, 1–77), the overall response rate, at least a very good partial response rate, and median progression-free survival time were 79.3%, 56.1%, and 24.4 months, respectively. This slightly lower performance compared to that in the IKEMA study may be attributed to the well-known poor prognostic impact of lenalidomide refractoriness (len-R), developed by all our patients during maintenance therapy, and to a higher proportion of patients with extramedullary disease present in our series, which was identified as the only factor significantly affecting the PFS in multivariable analysis. The median overall survival was not reached, as in the pivotal trial, while the 1-year survival probability was 85.1%. Regarding the safety profile, our findings were consistent with those of the IKEMA trial, with no new safety signals reported. Conclusions: These real-world data support the use of IsaKd as a valuable option for len-R MM patients relapsing after the first-line therapy, including ASCT and lenalidomide maintenance.
- Open Access
- 13 February 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (3) , 1443-1458
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts
Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+ 1q). While many mechanisms of resistance have been associated with + 1q alterations (e.g. CD38 downregulation, impairment of complement-dependent cytotoxicity, or induction of immunosuppression), the precise genetic or pathogenetic factors responsible for these alterations are still being investigated. Although interphase fluorescence in situ hybridisation (iFISH) is the gold standard for the detection of + 1q abnormalities used by the majority of diagnostic laboratories worldwide, there are no universally recognised cut-offs for + 1q positivity or a threshold for clinical meaningfulness. Because iFISH alone is insufficient to elucidate the extent of + 1q and other cytogenetic abnormalities in MM, sequencing-based methods could be adopted. The second revision of the international staging system for MM recently recognised + 1q as a high-risk feature. There is increasing evidence that + 1q has a prognostic value and influences the duration of remission, suggesting that patients with MM and + 1q may benefit from tailored therapy. This review comprehensively summarises the most recent biological evidence and clinical data on + 1q abnormalities in MM. However, given the heterogeneous data available, it remains difficult to draw firm conclusions. In clinical practice, +1q alterations should be evaluated along with other cytogenetic abnormalities and other biological and clinical characteristics of the disease. Ongoing and future studies will help the full understanding of the role of + 1q in MM.
- 13 February 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (3) , 1443-1458
Open AccessOverview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts
Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+ 1q). While many mechanisms of resistance have been associated with + 1q alterations (e.g. CD38 downregulation, impairment of complement-dependent cytotoxicity, or induction of immunosuppression), the precise genetic or pathogenetic factors responsible for these alterations are still being investigated. Although interphase fluorescence in situ hybridisation (iFISH) is the gold standard for the detection of + 1q abnormalities used by the majority of diagnostic laboratories worldwide, there are no universally recognised cut-offs for + 1q positivity or a threshold for clinical meaningfulness. Because iFISH alone is insufficient to elucidate the extent of + 1q and other cytogenetic abnormalities in MM, sequencing-based methods could be adopted. The second revision of the international staging system for MM recently recognised + 1q as a high-risk feature. There is increasing evidence that + 1q has a prognostic value and influences the duration of remission, suggesting that patients with MM and + 1q may benefit from tailored therapy. This review comprehensively summarises the most recent biological evidence and clinical data on + 1q abnormalities in MM. However, given the heterogeneous data available, it remains difficult to draw firm conclusions. In clinical practice, +1q alterations should be evaluated along with other cytogenetic abnormalities and other biological and clinical characteristics of the disease. Ongoing and future studies will help the full understanding of the role of + 1q in MM.
- Open Access
- 3 February 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70042
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority were under 70 years old (60.8%), predominantly female (56.9%), and heavily pretreated, with 74.5% being triple‐class refractory (TCR); 32.1% of the 28 patients with cytogenetic data had high‐risk abnormalities. The overall response rate (ORR) was 56.9%, including 3 patients with stringent complete response (sCR), 4 with CR, and 7 with very good partial response (VGPR). Neither age, number of prior therapies, TCR status, nor time from Dara refractoriness to IsaPd initiation significantly affected response rates.Median progression‐free survival (PFS) was 5.8 months, with a 12‐month PFS probability of 30.6%. Baseline hemoglobin (Hb) levels were a key predictor of PFS: patients with Hb < 11.8 g/L had a 3.5‐fold increased risk of progression, with a median PFS of 4.6 months compared to 22 months in those with higher Hb.Median overall survival (OS) was 21.0 months, with a 12‐month OS probability of 63.4%. Lower Hb levels (< 11 g/L) were associated with a tenfold increased risk of mortality.Among the 28 patients who underwent FISH analysis, while no significant difference in mortality risk was observed, those with high‐risk cytogenetic abnormalities exhibited a nearly tenfold increased risk of disease progression.These results suggest that IsaPd offers a meaningful option for Dara‐R patients, with Hb levels serving as a critical predictor of both PFS and OS. However, PFS remains modest, underscoring the need for novel combination therapies.
- 3 February 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70042
Open AccessEfficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority were under 70 years old (60.8%), predominantly female (56.9%), and heavily pretreated, with 74.5% being triple‐class refractory (TCR); 32.1% of the 28 patients with cytogenetic data had high‐risk abnormalities. The overall response rate (ORR) was 56.9%, including 3 patients with stringent complete response (sCR), 4 with CR, and 7 with very good partial response (VGPR). Neither age, number of prior therapies, TCR status, nor time from Dara refractoriness to IsaPd initiation significantly affected response rates.Median progression‐free survival (PFS) was 5.8 months, with a 12‐month PFS probability of 30.6%. Baseline hemoglobin (Hb) levels were a key predictor of PFS: patients with Hb < 11.8 g/L had a 3.5‐fold increased risk of progression, with a median PFS of 4.6 months compared to 22 months in those with higher Hb.Median overall survival (OS) was 21.0 months, with a 12‐month OS probability of 63.4%. Lower Hb levels (< 11 g/L) were associated with a tenfold increased risk of mortality.Among the 28 patients who underwent FISH analysis, while no significant difference in mortality risk was observed, those with high‐risk cytogenetic abnormalities exhibited a nearly tenfold increased risk of disease progression.These results suggest that IsaPd offers a meaningful option for Dara‐R patients, with Hb levels serving as a critical predictor of both PFS and OS. However, PFS remains modest, underscoring the need for novel combination therapies.
- Open Access
- 19 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6238
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review
Background/Objectives: Patients with multiple myeloma (MM) who relapse after exposure to lenalidomide in the context of their first-line therapy are becoming a growing and clinically relevant population. We performed a systematic review of available clinical trials evaluating the efficacy and safety of different therapeutic strategies for the treatment of patients with MM at first relapse after the frontline use of lenalidomide. Methods: Publications of interest were searched on the PubMed database. The following search terms were employed: relapsed multiple myeloma, refractory multiple myeloma, first relapse, second-line therapy, lenalidomide-refractory (Len-R) and lenalidomide-exposed (Len-Exp). Results: Overall, triplet regimens that included anti-CD38 antibodies, carfilzomib and dexamethasone achieved a more favorable PFS regardless of the number of prior therapies. Other trials also demonstrated a non-negligible benefit with combinations containing pomalidomide, particularly in early lines of therapy. However, the variable number of patients with Len-Exp/Len-R disease enrolled in these studies and the limited number of those analyzed after progression following frontline lenalidomide make it difficult to select an “optimal” choice for the treatment of patients with MM at first relapse. Promising results have been more recently obtained by using combo therapies, including belantamab mafodotin and, above all, immunotherapies with CAR-T cells, and ongoing clinical trials are exploring the role of bispecific antibodies and CELMoDs in this population of patients. Conclusions: In the absence of clear-cut data regarding the specific effects of available regimens on patients with MM who are refractory or have relapsed after first-line therapies including lenalidomide, novel approaches based on different types of immune strategies are expected to further improve the clinical outcome of these patients.
- 19 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6238
Open AccessStrengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review
Background/Objectives: Patients with multiple myeloma (MM) who relapse after exposure to lenalidomide in the context of their first-line therapy are becoming a growing and clinically relevant population. We performed a systematic review of available clinical trials evaluating the efficacy and safety of different therapeutic strategies for the treatment of patients with MM at first relapse after the frontline use of lenalidomide. Methods: Publications of interest were searched on the PubMed database. The following search terms were employed: relapsed multiple myeloma, refractory multiple myeloma, first relapse, second-line therapy, lenalidomide-refractory (Len-R) and lenalidomide-exposed (Len-Exp). Results: Overall, triplet regimens that included anti-CD38 antibodies, carfilzomib and dexamethasone achieved a more favorable PFS regardless of the number of prior therapies. Other trials also demonstrated a non-negligible benefit with combinations containing pomalidomide, particularly in early lines of therapy. However, the variable number of patients with Len-Exp/Len-R disease enrolled in these studies and the limited number of those analyzed after progression following frontline lenalidomide make it difficult to select an “optimal” choice for the treatment of patients with MM at first relapse. Promising results have been more recently obtained by using combo therapies, including belantamab mafodotin and, above all, immunotherapies with CAR-T cells, and ongoing clinical trials are exploring the role of bispecific antibodies and CELMoDs in this population of patients. Conclusions: In the absence of clear-cut data regarding the specific effects of available regimens on patients with MM who are refractory or have relapsed after first-line therapies including lenalidomide, novel approaches based on different types of immune strategies are expected to further improve the clinical outcome of these patients.
- 31 May 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (4) , e3290
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials
The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.
- 31 May 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (4) , e3290
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials
The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.
- 28 May 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5691-5701
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
Myeloma with extramedullary plasmacytomas not adjacent to bone (EMP) is associated with an extremely poor outcome compared with paraosseous plasmacytomas (PP) as current therapeutic approaches are unsatisfactory. The role of new molecules and in particular of monoclonal antibodies is under investigation. To determine whether daratumumab-based regimens are effective for myeloma with EMP, we report herein an initial multicenter observational analysis of 102 myeloma patients with EMP (n = 10) and PP (n = 25) at diagnosis and EMP (n = 28) and PP (n = 39) at relapse, treated with daratumumab-based regimens at 11 Haematological Centers in Italy. EMP and PP at diagnosis were associated with higher biochemical (90% vs. 96%, respectively) and instrumental ORR (86% vs. 83.3%, respectively), while at relapse, biochemical (74% vs. 73%) and instrumental (53% vs. 59%) ORR were lower. Median OS was inferior in EMP patients compared with patients with PP both at diagnosis (21.0 months vs. NR) (p = 0.005) and at relapse (32.0 vs. 40.0 months) (p = 0.428), although, during relapse, there was no statistically significant difference between the two groups. Surprisingly, at diagnosis, median TTP and median TTNT were not reached either in EMP patients or PP patients and during relapse there were no statistically significant differences in terms of median TTP (20 months for two groups), and median TTNT (24 months for PP patients vs. 22 months for EMP patients) between the two groups. Median TTR was 1 month in all populations. These promising results were documented even in the absence of local radiotherapy and in transplant-ineligible patients.
- 28 May 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5691-5701
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
Myeloma with extramedullary plasmacytomas not adjacent to bone (EMP) is associated with an extremely poor outcome compared with paraosseous plasmacytomas (PP) as current therapeutic approaches are unsatisfactory. The role of new molecules and in particular of monoclonal antibodies is under investigation. To determine whether daratumumab-based regimens are effective for myeloma with EMP, we report herein an initial multicenter observational analysis of 102 myeloma patients with EMP (n = 10) and PP (n = 25) at diagnosis and EMP (n = 28) and PP (n = 39) at relapse, treated with daratumumab-based regimens at 11 Haematological Centers in Italy. EMP and PP at diagnosis were associated with higher biochemical (90% vs. 96%, respectively) and instrumental ORR (86% vs. 83.3%, respectively), while at relapse, biochemical (74% vs. 73%) and instrumental (53% vs. 59%) ORR were lower. Median OS was inferior in EMP patients compared with patients with PP both at diagnosis (21.0 months vs. NR) (p = 0.005) and at relapse (32.0 vs. 40.0 months) (p = 0.428), although, during relapse, there was no statistically significant difference between the two groups. Surprisingly, at diagnosis, median TTP and median TTNT were not reached either in EMP patients or PP patients and during relapse there were no statistically significant differences in terms of median TTP (20 months for two groups), and median TTNT (24 months for PP patients vs. 22 months for EMP patients) between the two groups. Median TTR was 1 month in all populations. These promising results were documented even in the absence of local radiotherapy and in transplant-ineligible patients.